AMENDMENTS TO THE CLAIMS

1. (currently amended) A compound having the structure

~~I-X-(C=Y)$_m$-L-A~~



wherein ~~I is an HIV protease inhibitor selected from the group consisting of lopinavir, said inhibitor lacking only a hydroxyl or an amino group,~~

~~X is O or NR wherein R is H or lower alkyl,~~

Y is O, ~~S or NH,~~

m is 0 ~~or 1~~,

L is a linker comprising ~~from~~ 0 ~~to 40~~ carbon atoms ~~arranged in a straight chain or a branched chain, saturated or unsaturated, and containing up to two ring structures and 0-20 heteroatoms, with the proviso that not more than two heteroatoms may be linked in sequence~~, and

A is an activated ester ~~functionality chosen from the group consisting of active esters, isocyanates, isothiocyanates, thiols, imidoesters, anhydrides, maleimides, thiolactones, diazonium groups and aldehydes~~.

2. (cancelled)

3. (currently amended) The compound of claim 1 wherein ~~X is O, Y is O and m is 1~~ A is succinimido-oxycarbonyl.

4-20 (cancelled)

21. (previously presented) The compound O$^5$-(succinimido-oxycarbonyl-butyryl-aminocaproyl)-lopinavir.

22. (previously presented) The compound O$^5$-[4'-(succinimido-oxycarbonyl)-benzoyl-aminocaproyl]-lopinavir.

23-30 (cancelled)

31. (currently amended) A compound having the structure

~~[I-X-(C=Y)$_m$-L-Z]$_n$-P~~



wherein ~~I is an HIV protease inhibitor selected from the group consisting of lopinavir, said inhibitor lacking only a hydroxyl or an amino group,~~

~~X is O or NR wherein R is H or lower alkyl,~~

Y is O, S, or NH,

m is 0 or 1,

L is a linker comprising 0 to 40 carbon atoms arranged in a straight chain or a branched chain, saturated or unsaturated, and further comprising up to two ring structures and 0-20 heteroatoms, with the proviso that not more than two heteroatoms are linked in sequence,

Z is a moiety selected from the group consisting of -CONH-, -NHCO-, -NHCONH-, -NHCSNH-, -OCONH-, -NHOCO-, -S-, -NH(C=NH)-, -N=N-, -NH-, and  ,

P is selected from the group consisting of polypeptides, polysaccharides and synthetic polymers, and

n is a number from 1 to 50 per 50 kilodaltons molecular weight of P.

32. (cancelled)

33. (original) The compound of claim 31 wherein P is an aminated dextran.

34. (original) The compound of claim 31 wherein P is bovine serum albumin.

35. (original) The compound of claim 31 wherein P is keyhole limpet hemocyanin.

36. (original) The compound of claim 31 wherein P is *Limulus polyphemus* hemocyanin.

37. (original) The compound of claim 31 wherein P is bovine thyroglobulin.

38-47 (cancelled)

48. (previously presented) The compound $O^5$-(succinimido-oxycarbonyl-butyryl-aminocaproyl)-lopinavir conjugate with KLH.

49. (previously presented) The compound $O^5$-[4'-(succinimido-oxycarbonyl)-benzoyl-aminocaproyl]-lopinavir conjugate with BSA.

50-51 (cancelled)

52. (currently amended) A compound having the structure

~~[I-X-(C=Y)$_m$-L-Z]$_n$-Q~~



wherein ~~I is an HIV protease inhibitor selected from the group consisting of lopinavir, said inhibitor lacking only a hydroxyl or an amino group,~~

~~X is O or NR wherein R is H or lower alkyl,~~

Y is O, S, or NH,

m is 0 or 1,

L is a linker comprising 0 to 40 carbon atoms arranged in a straight chain or a branched chain, saturated or unsaturated, and further comprising up to two ring structures and 0-20 heteroatoms, with the proviso that not more than two heteroatoms are linked in sequence,

Z is a moiety ~~chosen~~ selected from the group consisting of -CONH-, -NHCO-,-NHCONH-, -NHCSNH-, -OCONH-, -NHOCO-, -S-, -NH(C=NH)-, -N=N-, -NH-, and  ,

Q is selected from the group consisting of non-isotopic labels,

and n is a number from 1 to 50 per 50 kilodaltons molecular weight of Q.

53. (cancelled)

54. (original) The compound of claim 52 wherein Q is biotin.

55. (cancelled)

56. (previously presented) The compound $O^c$-[4'-(1-biotinyl-amino-3,6-dioxa-octylamino)-terephthaloyl-aminocaproyl]-lopinavir.

57-58 (cancelled)

59. (currently amended) An antibody generated in response to a compound having the structure:

~~[I-X-(C=Y)$_m$-L-Z]$_n$-P~~



wherein ~~I is an HIV protease inhibitor selected from the group consisting of lopinavir, said inhibitor lacking only a hydroxyl or an amino group;~~

~~X is O or NR wherein R is H or lower alkyl;~~

Y is O, S, or NH,

m is 0 or 1,

L is a linker comprising 0 to 40 carbon atoms arranged in a straight chain or a branched chain, saturated or unsaturated, and further comprising up to two ring structures and 0-20 heteroatoms, with the proviso that not more than two heteroatoms are linked in sequence,

Z is a moiety selected from the group consisting of -CONH-, -NHCO-, -NHCONH-, -NHCSNH-, -OCONH-, -NHOCO-, -S-, -NH(C=NH)-, -N=N-, -NH-, and  ,

P is selected from the group consisting of polypeptides, a polysaccharides, and synthetic polymers,

and n is a number from 1 to 50 per 50 kilodaltons molecular weight of P.

60-65 (cancelled)

66. (original) An antibody generated in response to the compound of claim 48.

67-80 (cancelled)

81. (new) A compound having the structure



wherein

Y is O,

m is 1,

L is a linker comprising from 1 to 40 carbon atoms arranged in a straight chain or a branched chain, saturated or unsaturated, and containing up to two ring structures and 0-20 heteroatoms, with the proviso that not more than two heteroatoms may be linked in sequence, and

A is an activated ester.

82. (new) The compound of claim 81 wherein A is succinimido-oxycarbonyl.